In Reply We would like to thank Dr Inoue and colleagues for their interest in our recent Original Investigation.¹ As suggested by Inoue and colleagues, we now provide some additional information about our analyses. Our life expectancy calculations used age-adjusted hazards and age-specific mortality rates, based on the data of individuals at different ages and different health states. In the third transition (ie, mortality among those with cardiovascular disease [CVD]), stratified analyses among participants who acquired CVD during the study period and participants who already had a history of CVD at baseline consistently showed that high-normal thyroid function is linked to a higher mortality risk than low-normal thyroid function. In addition, sensitivity analyses restricting the follow-up time to different lengths (ie, 6, 8, 10 years of follow-up) yielded similar results. These data point toward a persistent effect of thyroid hormones on mortality risk across time.

回复我们要感谢Inoue博士及其同事对我们最近的原始调查感兴趣。^1个正如Inoue和同事建议的那样，我们现在提供有关分析的其他信息。基于不同年龄和不同健康状况的个体数据，我们的预期寿命计算使用了经过年龄调整的危害和特定年龄的死亡率。在第三个过渡期（即心血管疾病[CVD]的死亡率）中，对在研究期间获得CVD的参与者和在基线时已有CVD病史的参与者进行的分层分析一致地表明，甲状腺功能正常与高脂血症有关。比低正常的甲状腺功能具有更高的死亡风险。此外，敏感性分析将随访时间限制在不同的长度（即随访6、8、10年），结果相似。